688180 Panoramica delle azioni Shanghai Junshi Biosciences Co., Ltd., società biofarmaceutica, è impegnata nella scoperta, nello sviluppo e nella commercializzazione di vari farmaci nelle aree terapeutiche dei tumori maligni, delle malattie neurologiche, autoimmuni, metaboliche croniche, del sistema nervoso e infettive nella Repubblica Popolare Cinese. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Shanghai Junshi Biosciences Co., Ltd. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Shanghai Junshi Biosciences Prezzi storici delle azioni Prezzo attuale dell'azione HK$25.78 Massimo di 52 settimane HK$40.15 Minimo di 52 settimane HK$23.08 Beta 0.43 Variazione di 1 mese -15.20% Variazione a 3 mesi -25.08% Variazione di 1 anno -33.59% Variazione a 3 anni -60.15% Variazione a 5 anni n/a Variazione dall'IPO -71.03%
Notizie e aggiornamenti recenti
Shanghai Junshi Biosciences Co., Ltd.'s JS212 Injection Receives the Acceptance Notice for Theinvestigational New Drug Application Jan 08
Shanghai Junshi Biosciences Co., Ltd. Receives Conditional Approval from the National Medical Products Administration Jan 06
Shanghai Junshi Biosciences Co., Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025 Dec 27
Shanghai Junshi Biosciences Co., Ltd. Announces Board and Committee Changes Dec 20 Shanghai Junshi Biosciences Co., Ltd.(SHSE:688180) dropped from SSE 180 Index
Shanghai Junshi Biosciences Co., Ltd. Announces Change of Address of Principal Place of Business in Hong Kong Nov 30 Vedi altri aggiornamenti
Shanghai Junshi Biosciences Co., Ltd.'s JS212 Injection Receives the Acceptance Notice for Theinvestigational New Drug Application Jan 08
Shanghai Junshi Biosciences Co., Ltd. Receives Conditional Approval from the National Medical Products Administration Jan 06
Shanghai Junshi Biosciences Co., Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025 Dec 27
Shanghai Junshi Biosciences Co., Ltd. Announces Board and Committee Changes Dec 20 Shanghai Junshi Biosciences Co., Ltd.(SHSE:688180) dropped from SSE 180 Index
Shanghai Junshi Biosciences Co., Ltd. Announces Change of Address of Principal Place of Business in Hong Kong Nov 30 Shanghai Junshi Biosciences Co., Ltd. Announces Change of Address of Principal Place of Business in Hong Kong
Shanghai Junshi Biosciences Co., Ltd. Announces the Approval of New Drug Application for Ongericimab Injection Oct 14
Shanghai Junshi Biosciences Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Sep 30
Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial Sep 26
Shanghai Junshi Biosciences Co., Ltd. Receives Approval by the European Commission for Marketing of Toripalimab Sep 24
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma Aug 13
Shanghai Junshi Biosciences Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug Application for WJ47156 Tablets Jul 09
Shanghai Junshi Biosciences Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024 Jun 28
Shanghai Junshi Biosciences Co., Ltd. Receives the Drug Registration Certificate Issued by the National Medical Products Administration Jun 26
Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes Jun 24
Shanghai Junshi Biosciences Co., Ltd Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer Jun 19
Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration Jun 14
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma Jun 13
Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 21, 2024 May 31 Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer Apr 10
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection Apr 03
Shanghai Junshi Biosciences Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Mar 30 Shanghai Junshi Biosciences Co., Ltd. Announces Acceptation of New Drug Application of Toripalimab by Singapore Health Sciences Authority
Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer Jan 13 Shanghai Junshi Biosciences Co., Ltd. and Topalliance Biosciences Inc Appoints Li Ning as Vice Chairman of the Third Session of the Board
Shanghai Junshi Biosciences Co., Ltd. Announces Publication of Results from Toripalimab, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine Jan 10
Shanghai Junshi Biosciences Co., Ltd. Announces New Indications of TUOYI and MINDEWEI Included in New Edition of National Reimbursement Drug List Dec 13 Shanghai Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia's TGA
Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association Nov 29
Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma Oct 28
Shanghai Junshi Biosciences Co., Ltd. Directors Appointments Oct 21
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab for the First-Line Treatment of Melanoma Met Primary Endpoint Sep 26
Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares. Sep 12 Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Notice of Approval for Clinical Trial
Shanghai Junshi Biosciences Co., Ltd. Announces Resignation of Wu Hai as Non-Executive Director Aug 31 Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares. Aug 28
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-Linetreatment of Advanced RCC Jul 12
Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes Jul 01
Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Acceptance Notice For the Investigational New Drug Application Jun 20 Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 30, 2023
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple - Negative Breast Cancer May 24
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Chemotherapy for the First-Line Treatment of ES-SCLC Met Primary Endpoint May 08
Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02 Feb 16
Shanghai Junshi Biosciences Co., Ltd. Announces JS401 Injection Receival the Acceptance Notice for The Investigational New Drug Application Feb 01 Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2022 Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of NDA for VV116 in China
Shanghai Junshi Biosciences Co., Ltd, Shanghai Juntop Biosciences Co., Ltd. and Vigonvita Life Sciences Co., Ltd. Announce Progress of the Clinical Studies of VV116 Jan 03
Shanghai Junshi Biosciences Co., Ltd. Receives Acceptance Notice for the Investigational New Drug Application Dec 31
Shanghai Junshi Biosciences Co., Ltd Announces Nejm Publication of Results of Phase 3 Study of Vv116 Versus Paxlovid for Adults At High Risk for Progression to Severe Covid-19 Dec 30
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma Dec 26
Shanghai Junshi Biosciences Co., Ltd. Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting Dec 13
Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes Dec 10
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Marketing Authorization Application of Toripalimab Dec 06
Shanghai Junshi Biosciences Co., Ltd Submits Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory Agency Nov 25
Shanghai Junshi Biosciences Co., Ltd. Announces Receiving the Notice of Approval for Supplemental Drug Application Issued by the National Medical Products Administration Nov 22
Shanghai Junshi Biosciences Co., Ltd. Announces Submission of A Marketing Authorization Application to the European Medicines Agency for Toripalimab Nov 15
Shanghai Junshi Biosciences Co., Ltd. Receives the Notice of Approval for Clinical Trial Issued by the National Medical Products Administration Oct 31
Shanghai Junshi Biosciences Co., Ltd. to Report Nine Months, 2022 Results on Oct 28, 2022 Oct 19
Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology Oct 13
Shanghai Junshi Biosciences Co., Ltd Receives NMPA Approval of sNDA for Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Non-squamous Non-Small Cell Lung Cancer Sep 21 Suzhou Junjing Biomedical Technology Co., Ltd. Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor) Shanghai Junshi Biosciences Co., Ltd. to Report Q2, 2022 Results on Aug 30, 2022
Shanghai Junshi Biosciences Co., Ltd. Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma Jul 22
Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial Issued by National Medical Products Administration Jul 13
Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma Jul 07
Shanghai Junshi Biosciences Co., Ltd. and Risen (Suzhou) Pharma Tech Co., Ltd. Announces FDA Approval of Investigational New Drug Application for JS105 Jul 05
Shanghai Junshi Biosciences Co., Ltd. Appoints Zou Jianjun as Executive Director Jun 30 Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 29, 2022
Shanghai Junshi Biosciences Co., Ltd. Announces PAXLOVID Phase III Registrational Trial for Early Treatment of Mild to Moderate Covid-19 May 26 Shanghai Junshi Biosciences Co., Ltd. Announces Vv116 Versus Paxlovid for Early Treatment of Mild to Moderate Covid-19 Reaches Primary Endpoint in Phase Iii Registrational Clinical Study Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination with Paclitaxel and Cisplatin in First-Line Treatment of Advanced or Distant Metastatic Esophageal Squamous Cell Carcinoma May 18
Shanghai Junshi Biosciences Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug Application
Shanghai Junshi Biosciences Co., Ltd. Updates on Biologics License Application to the Fdaof Toripalimab for Treatment of Nasopharyngealcarcinoma May 04 Rendimenti per gli azionisti 688180 CN Biotechs CN Mercato 7D -5.7% -3.2% -4.0% 1Y -33.6% -23.2% 6.4%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 688180 ha avuto una performance inferiore rispetto al CN Biotechs che ha registrato un rendimento -23.2 % nell'ultimo anno.
Rendimento vs Mercato: 688180 ha avuto una performance inferiore al mercato CN che ha registrato un rendimento 6.4 % nell'ultimo anno.
Volatilità dei prezzi Is 688180's price volatile compared to industry and market? 688180 volatility 688180 Average Weekly Movement 5.3% Biotechs Industry Average Movement 7.8% Market Average Movement 8.2% 10% most volatile stocks in CN Market 12.1% 10% least volatile stocks in CN Market 5.1%
Prezzo delle azioni stabile: 688180 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato CN.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di 688180 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Shanghai Junshi Biosciences Co., Ltd., società biofarmaceutica, è impegnata nella scoperta, nello sviluppo e nella commercializzazione di vari farmaci nelle aree terapeutiche dei tumori maligni, delle malattie neurologiche, autoimmuni, metaboliche croniche, del sistema nervoso e infettive nella Repubblica Popolare Cinese. La società è stata fondata nel 2012 e ha sede a Shanghai, nella Repubblica Popolare Cinese.
Mostra di più Shanghai Junshi Biosciences Co., Ltd. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Shanghai Junshi Biosciences con la sua capitalizzazione di mercato? 688180 statistiche fondamentali Capitalizzazione di mercato CN¥21.98b Guadagni(TTM ) -CN¥1.80b Ricavi(TTM ) CN¥1.79b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 688180 Conto economico (TTM ) Ricavi CN¥1.79b Costo del fatturato CN¥622.89m Profitto lordo CN¥1.16b Altre spese CN¥2.97b Guadagni -CN¥1.80b
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
Mar 28, 2025
Utile per azione (EPS) -1.83 Margine lordo 65.15% Margine di profitto netto -100.90% Rapporto debito/patrimonio netto 43.8%
Come si è comportato 688180 nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/08 22:31 Prezzo dell'azione a fine giornata 2025/01/08 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Shanghai Junshi Biosciences Co., Ltd. è coperta da 18 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Congmin Yuan Citic Securities Co., Ltd. Tan Huan Gan Citic Securities Co., Ltd. Muk Tsz Yung Citigroup Inc
Mostra 15 altri analisti 
